Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 86 Biopharm R&D efforts reflect Novo Nordisk's commitment to satisfy unmet patient needs Aim to develop subcutaneous haemophilia products and long-acting growth hormone Novo Nordisk Biopharm portfolio Pursue leadership in HAEMOPHILIA Strengthen leadership in GROWTH DISORDERS Pursue bolt-on opportunities Pursue subcutaneous delivery of long-acting coagulation factors and bypassing agents Bring long-acting growth hormone somapacitan to market and expand indications Identify bolt-on acquisition or in-licensing opportunities in adjacent disease area changing diabetes® Haemophilia Growth hormone Research/ preclinical Phase 1/2 N8-GP sc concizumab Phase 3 N8-GP IV somapacitan¹ NovoEight® Refixia® NovoThirteenⓇ Approved/ Launched Norditropin® NovoSevenⓇ 1 Somapacitan is currently in phase 3 for adult growth hormone deficiency and phase 2 for growth hormone deficiency in children Note: NovoThirteenⓇ and Refixia® are the brand names in the majority of countries, whereas these products are marketed as TRETTENⓇ and RebinynⓇ respectively in the US sc: Subcutaneous; IV: Intravenous novo nordisk

View entire presentation